儿科 GVHD 低风险类固醇减量试验
GVHD 儿童的系列反应和生物标志物指导的类固醇锥度
急性移植物抗宿主病 (GVHD) 的标准治疗方法是使用泼尼松等类固醇药物抑制供体免疫细胞的活性。 虽然大多数 GVHD,尤其是儿童,对治疗反应良好,但有时(大约 1/3 的时间)对类固醇没有反应或反应不会持续。 在这些情况下,GVHD 可能变得危险甚至危及生命。 不幸的是,医生无法根据症状严重程度或对类固醇的初始反应来预测谁会对治疗产生良好反应。 因此,几乎所有发生 GVHD 的儿童都接受了长疗程的高剂量类固醇治疗,尽管这意味着许多患者接受的治疗比他们可能需要的要多。 类固醇治疗可引起短期并发症,如感染、高血糖、高血压、肌肉无力、抑郁、焦虑和睡眠问题,以及长期并发症,如骨骼损伤、眼睛白内障和生长迟缓。 这些并发症的风险随着类固醇剂量的增加和治疗时间的延长而增加。 重要的是要找到减少不需要长期疗程患者类固醇治疗的方法。
进行这项研究的医生开发了一种血液测试(GVHD 生物标志物),可以预测患者对类固醇的反应是否良好。 研究小组发现,在治疗开始时和治疗的前两周 GVHD 生物标志物较低的儿童对类固醇的反应率非常高。 在这项研究中,研究小组将在治疗期间监测 GVHD 症状和生物标志物,并在预计对治疗反应良好的 GVHD 患者中迅速减少类固醇。 研究小组将评估有多少患者对较低的类固醇剂量反应良好,以及会出现哪些类固醇并发症。 研究小组还将使用调查来获得患者自己对其生活质量的评估(低至 5 岁)。
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5S
- The Hospital for Sick Children
-
-
-
-
California
-
Los Angeles、California、美国、90027
- Children's Hospital of Los Angeles
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- Children's National Hospital
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- Children's Healthcare of Atlanta
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- Boston Children's Hospital Dana Farber Cancer Institute
-
-
New York
-
New York、New York、美国、10065
- Memorial Sloan Kettering Cancer Center
-
New York、New York、美国、10029
- Icahn School of Medicine at Mount Sinai
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Nashville、Tennessee、美国、37235
- Vanderbilt University Medical Center
-
-
Texas
-
Houston、Texas、美国、77030
- Texas Children's Hospital, Baylor College of Medicine
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- Medical College of Wisconsin / Children's Wisconsin
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
描述
纳入标准:
- 符合明尼苏达标准风险标准的新诊断 GVHD,但限于皮疹 <50% 体表面积(I 级 GVHD)或孤立的上消化道受累的 GVHD 除外
- 生物标志物的安娜堡 1 GVHD
- GVHD 之前未进行全身治疗(允许局部治疗和非吸收性类固醇)
- 任何供体类型、HLA 匹配、预处理方案都是可以接受的
- 筛选时年龄为 0-21 岁
- 性能得分(Lansky/Karnofsky)≥70%
- 从患者或法定代表处获得的签署并注明日期的书面知情同意书以及能够提供同意书的儿科患者的同意书
排除标准:
- 入组前用 >0.5 mg/kg 强的松或任何类固醇治疗 GVHD 治疗超过 3 天的 GVHD 患者
- 在急性 GVHD 发作前 7 天内因任何适应症接受皮质类固醇 >0.1 mg/kg 泼尼松(或其他类固醇等效物)的患者,肾上腺功能不全、输血前用药/静脉注射药物或间歇性使用以控制症状(如恶心/呕吐)除外
- 需要撤消全身免疫抑制的复发、进展或持续性恶性肿瘤或其他病症(例如,已知的供体嵌合体下降)
- 感染不受控制的患者(即尽管治疗但与感染相关的进行性症状、尽管治疗但微生物培养持续阳性、对治疗无反应的病毒再激活或任何其他严重感染的证据)
- 入组后 7 天内出现严重器官功能障碍,包括需要透析、机械通气或氧气补充超过 40% FiO2
- 直接胆红素 >2 mg/dl 或 ALT 或 AST > 正常上限的 5 倍证明有明显的肝病
- 根据机构实践计算的肌酐清除率或估计肾小球滤过率 <30 毫升/分钟
- 类似于新发慢性 GVHD 或重叠综合征的临床表现在入组前或入组时出现
- 怀孕的患者
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:类固醇锥度
所有入组患者开始使用相同剂量的类固醇治疗 GVHD,在研究开始后第 1 周和第 2 周采集血样,生物标志物加上临床反应决定类固醇治疗的继续方式
|
泼尼松起始剂量为 0.5 mg/kg;对于临床反应良好且生物标志物持续低的患者,将迅速减量;那些没有临床反应或生物标志物增加的人将根据他们的主治医师计划或护理标准进行治疗
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants Who Were Responders (CR, VGPR, or PR) on Day 28 With Low Cumulative Steroid Exposure
大体时间:study day 28
|
Number of participants who were responders. Responders are patients with low-risk GVHD (Minnesota standard risk/Ann Arbor 1) who are in CR, VGPR or PR on day 28 and whose cumulative prednisone (or other steroid equivalent) exposure during the first four weeks of treatment is ≤13.5 mg/kg and who have had no intervening additional GVHD therapy for those in CR or VGPR. Complete Response (CR): All evaluable organs (skin, liver, GI tract) stage 0. Very Good Partial Response (VGPR): Any response that approximates a CR with the exception of rash <25% body surface area. Partial Response (PR): An improvement in one or more organ involved with GVHD symptoms without worsening in others. |
study day 28
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants Who Achieved a Treatment Response by Day 28
大体时间:study day 28
|
Number of participants who achieve a treatment response by day 28 of treatment.
Treatment responses are defined as complete response (CR), very good partial response (VGPR), or partial response (PR).
For a response to be scored as CR, VGPR, or PR on day 28, the patient must be in response on day 28 and have had no intervening systemic therapy for acute GVHD other than steroids.
|
study day 28
|
|
Number of Participants Who Developed Serious Infection
大体时间:study day 90
|
Number of patients who develop serious infections (viral, bacterial, fungal, parasitic) Serious infections are defined using the standardized criteria widely used for clinical trials at academic BMT centers, such as life-threatening fungal infections or hemorrhagic cystitis from BK viral infection and include clinically significant CMV infections that require anti-viral treatment regardless of end-organ damage, given the toxicity of such treatments. Serious infections include any viral, bacterial, fungal or parasitic infections that requires systemic treatment. |
study day 90
|
|
Number of Participants Alive at 6 Months
大体时间:6 months
|
Overall survival assessed by number of participants alive at 6 months OS is defined as the time from the first dose of study treatment to the date of death (whatever the cause). |
6 months
|
|
Overall Survival at 12 Months
大体时间:12 months
|
Overall survival at 12 months OS is defined as the time from the first dose of study treatment to the date of death (whatever the cause). |
12 months
|
|
Number of Participants Who Had Non-Relapse Mortality (NRM) at 6 Months
大体时间:6 months
|
Number of Participants who had NRM at 6 months Survival will be tracked during the study, any deaths will be collected. Any death that occurs after hematopoietic stem cell transplantation (HCT) not attributable to relapse of the underlying disease will be considered a non-relapse death. |
6 months
|
|
Cumulative Incidence of Non-Relapse Mortality (NRM) at 12 Months
大体时间:12 months
|
Cumulative incidence of NRM at 12 months Survival will be tracked during the study, any deaths will be collected. Any death that occurs after HCT not attributable to relapse of the underlying disease will be considered a non-relapse death. |
12 months
|
|
Number of Participants Who Relapsed at 6 Months
大体时间:6 months
|
Number of participants who relapsed of the underlying malignancy at 6 months.
|
6 months
|
|
Relapse Rate at 12 Months
大体时间:12 months
|
Relapse rate at 12 months Relapse, including date of relapse, of the underlying malignancy will be reported. |
12 months
|
|
Cumulative Incidence of Chronic GVHD
大体时间:12 months
|
Cumulative incidence of chronic GVHD requiring systemic steroid treatment by one year from enrollment
|
12 months
|
|
Cumulative Steroid Dose at Study Day 28
大体时间:study day 28
|
Cumulative steroid dose at day 28 Steroid drug and dose is collected weekly for the first 4 weeks of study. |
study day 28
|
|
Cumulative Steroid Dose at Study Day 90
大体时间:study day 90
|
Cumulative steroid dose at day 90 Steroid drug and dose is collected weekly for the first 4 weeks of study, and bi-weekly through study day 90. |
study day 90
|
合作者和调查者
赞助
调查人员
- 首席研究员:John E Levine, MD, MS、Icahn School of Medicine at Mount Sinai
- 首席研究员:Muna Qayed, MD, MS、Children's Healthcare of Atlanta, Emory University School of Medicine
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.